Skip to main content

Table 2 HPV and HIV epidemiology and disease management input data

From: Cost-effectiveness analysis of human papillomavirus vaccination in South Africa accounting for human immunodeficiency virus prevalence

Parameter

Annual probability

 

HIV- subpopulation

Source

HIV+ subpopulation

Source

Mortality rate

 General mortality rate

Age 15: 0.09 %

[65]

Age 15: 0.10 %

[65]

Age 30: 0.20 %

Age 30: 4.62 %

Age 45: 0.51 %

Age 45: 7.71 %

Age 60: 1.56 %

Age 60: 29.72 %

Age 75: 5.31 %

Age 75: 37.38 %

HPV and HIV incidence

 HIV incidence rate in women

NA

-

Age 15: 0.025

[65]

Age 30: 0.004

Age 45: 0.001

Age 60: 0.001

65+ years: 0

 Oncogenic HPV incidence

0.041–0.390

[59]

0.110–1.000

[59, 66]

Cervical cancer parameters

 Cervical cancer mortality

0.110

[2]

0.291

[67]

 Cervical cancer cured

0.151

[2]

0.027

[67]

HPV screening-related parameters

 Screening coverage

13.6 %

[59]

13.6 %

[59]

 Screening ages

30–60 years

[63]

30–60 years

[63]

 Screening frequency

Every 3 years

WHO [27, 28]

Every 3 years

WHO [27, 28]

 CIN1 detected

0.58

[68]

0.58

[68]

 CIN2/3 detected

0.61

[68]

0.61

[68]

HPV-related disease management

 Proportion of women treated if CIN1 is detected

0.50

Assumption

0.50

Assumption

 CIN1 treatment success

0.90

Assumption

0.90

Assumption

 Proportion of women treated if CIN2/3 is detected

1

Assumption

1

Assumption

 CIN2/3 treatment success

0.90

Assumption

0.90

Assumption

  1. ASSA, Actuarial Society of South Africa; CIN, cervical intraepithelial neoplasia; CIN1, CIN grade 1; CIN2/3, CIN grade 2 or 3; HIV, human immunodeficiency virus; HIV-, HIV-negative; HIV+, HIV-positive; HPV, human papillomavirus; ICO, Institut Català d'Oncologia; Pap, Papanicolaou smear test